87 related articles for article (PubMed ID: 15609128)
21. Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
Lee SJ; Cha CD; Hong H; Choi YY; Chung MS
Breast Cancer; 2024 Jul; 31(4):717-725. PubMed ID: 38671211
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
23. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
Briest S; Wolff AC
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1243-53. PubMed ID: 17892424
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
25. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
Kim M; Kim H; Ahn SH; Tabatabaie V; Choi SW; Sohn G; Lee SB; Ko BS; Chung IY; Kim J; Lee JW; Son BH; Kim HJ
Breast Cancer Res Treat; 2020 Apr; 180(3):657-663. PubMed ID: 32072339
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer adjuvant endocrine therapy.
Cigler T; Goss PE
Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
28. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
29. Use of a Swedish T-score reference population for women causes a two-fold increase in the amount of postmenopausal Swedish patients that fulfill the WHO criteria for osteoporosis.
Ribom EL; Ljunggren O; Mallmin H
J Clin Densitom; 2008; 11(3):404-11. PubMed ID: 18280191
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
31. Sr and Fe relationship with hormone replacement therapy and bone mineral density.
Unfer TC; Müller EI; de Moraes Flores EM; Dressler VL; da Silva JC; Duarte MM; Emanuelli T
Clin Chim Acta; 2007 Sep; 384(1-2):113-7. PubMed ID: 17618614
[TBL] [Abstract][Full Text] [Related]
32. Cancer chemotherapy-induced osteoporosis: How common is it among Saudi Arabian cancer survivors.
Al Amri A; Sadat-Ali M
Indian J Cancer; 2009; 46(4):331-4. PubMed ID: 19749464
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
[TBL] [Abstract][Full Text] [Related]
34. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
35. Effect of parity on bone mineral density among postmenopausal Saudi Arabian women.
Sadat-Ali M; Al-Habdan I; Al-Mulhim AA; El-Hassan AY
Saudi Med J; 2005 Oct; 26(10):1588-90. PubMed ID: 16228061
[TBL] [Abstract][Full Text] [Related]
36. Impaired bone microenvironment: correlation between bone density and presence of disseminated tumor cells.
Kraemer B; Rothmund R; Banys M; Krawczyk N; Solomayer EF; Mack C; Wallwiener D; Fehm T
Anticancer Res; 2011 Dec; 31(12):4423-8. PubMed ID: 22199310
[TBL] [Abstract][Full Text] [Related]
37. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer.
Greep NC; Giuliano AE; Hansen NM; Taketani T; Wang HJ; Singer FR
Am J Med; 2003 Jun; 114(8):653-9. PubMed ID: 12798453
[TBL] [Abstract][Full Text] [Related]
38. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.
Koppelmans V; de Ruiter MB; van der Lijn F; Boogerd W; Seynaeve C; van der Lugt A; Vrooman H; Niessen WJ; Breteler MM; Schagen SB
Breast Cancer Res Treat; 2012 Apr; 132(3):1099-106. PubMed ID: 22205140
[TBL] [Abstract][Full Text] [Related]
39. FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment.
Tabatabai LS; Bloom J; Stewart S; Sellmeyer DE
J Clin Endocrinol Metab; 2016 Mar; 101(3):1257-62. PubMed ID: 26756114
[TBL] [Abstract][Full Text] [Related]
40. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.
Shapiro CL; Manola J; Leboff M
J Clin Oncol; 2001 Jul; 19(14):3306-11. PubMed ID: 11454877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
